Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 373 entries
View as:

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT05624606 Org: User:
Start: 11/28/22 End: 03/28/24 Due: 03/28/25

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT05608005 Org: User:
Start: 11/03/22 End: 02/13/24 Due: 02/13/25

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Phase: N/A Priority: Normal
NCT ID: NCT00743275 Org: User:
Start: 08/31/08 End: 11/30/08 Due: 11/30/09

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Phase: N/A Priority: Normal
NCT ID: NCT04142242 Org: User:
Start: 10/04/19 End: 05/25/22 Due: 05/25/23

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

Phase: N/A Priority: Normal
NCT ID: NCT00447525 Org: User:
Start: 02/28/07 End: 01/31/08 Due: 01/31/09

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT06838000 Org: User:
Start: 02/28/25 End: 12/01/26 Due: 12/01/27

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Phase: N/A Priority: Normal
NCT ID: NCT00594347 Org: User:
Start: 11/30/07 End: 04/30/09 Due: 04/30/10

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth

Phase: N/A Priority: Normal
NCT ID: NCT01948193 Org: User:
Start: 02/28/14 End: 06/30/15 Due: 06/30/16

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers

Phase: N/A Priority: Normal
NCT ID: NCT01001988 Org: User:
Start: 08/07/09 End: 10/16/13 Due: 10/16/14

Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT01346293 Org: User:
Start: 04/30/11 End: 09/30/13 Due: 09/30/14

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older

Phase: N/A Priority: Normal
NCT ID: NCT04762680 Org: User:
Start: 02/24/21 End: 06/29/23 Due: 06/29/24

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

Phase: N/A Priority: Normal
NCT ID: NCT01784874 Org: User:
Start: 02/28/13 End: 12/31/15 Due: 12/31/16

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Phase: N/A Priority: Normal
NCT ID: NCT00740155 Org: User:
Start: 08/31/08 End: 01/31/10 Due: 01/31/11

A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT01258595 Org: User:
Start: 11/30/10 End: 04/30/11 Due: 04/30/12

Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children

Phase: N/A Priority: Normal
NCT ID: NCT00771849 Org: User:
Start: 08/31/03 End: 05/31/04 Due: 05/31/05

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02492165 Org: User:
Start: 06/30/15 End: 06/30/16 Due: 06/30/17

Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan

Phase: N/A Priority: Normal
NCT ID: NCT02005536 Org: User:
Start: 12/31/13 End: 10/31/14 Due: 10/31/15

Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Phase: N/A Priority: Normal
NCT ID: NCT00383539 Org: User:
Start: 09/30/06 End: 12/31/07 Due: 12/31/08

Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

Phase: N/A Priority: Normal
NCT ID: NCT06583031 Org: User:
Start: 10/09/24 End: 09/28/25 Due: 09/28/26

Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Phase: N/A Priority: Normal
NCT ID: NCT00313911 Org: User:
Start: 07/31/06 End: 02/29/08 Due: 02/28/09

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Phase: N/A Priority: Normal
NCT ID: NCT01134263 Org: User:
Start: 10/05/10 End: 02/28/13 Due: 02/28/14

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Phase: N/A Priority: Normal
NCT ID: NCT00858468 Org: User:
Start: 04/30/05 End: 12/31/06 Due: 12/31/07

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia

Phase: N/A Priority: Normal
NCT ID: NCT04113330 Org: User:
Start: 01/31/20 End: 01/11/30 Due: 01/11/31

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Phase: N/A Priority: Normal
NCT ID: NCT05050318 Org: User:
Start: 09/08/21 End: 11/10/21 Due: 11/10/22

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT05639894 Org: User:
Start: 11/17/22 End: 05/02/25 Due: 05/02/26